Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| INT21-05-01 | CLO-Northwestern University | Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccine (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome | Cancer Prevention and Control CIRB | Available to Open | |
| INT22-09-01 | CP-CTNet_CLO-University of Wisconsin | A Randomized Trial of Apalutamide in Non-Muscle Invasive Bladder Cancer | Cancer Prevention and Control CIRB | Available to Open | |
| LungMAP | SWOG | A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| MAY2015-05-01 | CP-CTNet_CLO-Mayo Clinic | Randomized, double-blind, placebo-controlled trial of Meriva® (curcuminoids) as a candidate chemoprevention agent for gastric carcinogenesis | Cancer Prevention and Control CIRB | Available to Open | |
| MAY2016-07-01 | CP-CTNet_CLO-Mayo Clinic | Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated with Familial Adenomatous Polyposis | Cancer Prevention and Control CIRB | Completed | |
| MAY2016-07-01F | CP-CTNet_CLO-Mayo Clinic | Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01 Weekly Erlotinib for Familial Adenomatous Polyposis | Cancer Prevention and Control CIRB | Completed | |
| MAY2016-08-01 | CP-CTNet_CLO-Mayo Clinic | A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer | Cancer Prevention and Control CIRB | Available to Open | |
| MAY2017-09-01 | CP-CTNet_CLO-Mayo Clinic | Phase I Double-Blind, Placebo-Controlled Trial of 27 mg Dolcanatide (SP-333) to Demonstrate Colorectal Bioactivity in Healthy Volunteers | Cancer Prevention and Control CIRB | Completed | |
| MDA20-01-01 | CP-CTNet_CLO-MD Anderson | A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP) | Cancer Prevention and Control CIRB | Available to Open | |
| MDA20-02-01 | CP-CTNet_CLO-MD Anderson | Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A randomized, Phase IIb, Window of Opportunity Presurgical Trial. | Cancer Prevention and Control CIRB | Available to Open |